Cardio Diagnostics Holdings (CDIO) Net Equity Issued and Repurchased (2021 - 2026)

Cardio Diagnostics Holdings has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $3.7 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 7.88% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 71.1% YoY) and the FY2025 annual result came in at $3.8 million, down 69.31% from the prior year.
• Net Equity Issued and Repurchased rose to $3.7 million in Q1 2026 per CDIO's latest filing, from $263068.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $12.0 million in Q4 2022 and troughed at $116646.0 in Q3 2025.
• A 4-year average of $3.5 million and a median of $2.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2022 and 2025: Net Equity Issued and Repurchased surged 47844.14% in 2022, then slumped 96.43% in 2025.
• Over 4 years, Net Equity Issued and Repurchased stood at $12.0 million in 2022, then tumbled by 38.52% to $7.4 million in 2024, then plunged by 96.43% to $263068.0 in 2025, then jumped by 1304.0% to $3.7 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3.7 million, $263068.0, and $116646.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.